Psychedelics

Selections from the 2022 Psychiatric Times cover features.

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.

From the unique challenges of treating physician-patients to updates on MDMA and psilocybin research and access, here are highlights from the week in Psychiatric Times.

A new bill, the Breakthrough Therapies Act, would encourage the reclassification of MDMA and psilocybin from schedule I to schedule II drugs.

The second of a phase 3 study examining MDMA-AT just completed its final participant visit.

A single dose of psilocybin could help patients with treatment-resistant depression, according to a new study.

Classic psychedelic research is rapidly expanding...

Vol. 39, Issue 9 covers the latest in psychedelics research and development in psychiatry.

In a well-blinded study, researchers investigated and directly compared the acute effects of LSD and psilocybin in healthy participants.

How can a robust understanding of the altered-state experience drive the development of therapeutic frameworks that are designed around that experience?

The underlying neural mechanisms identified may help clinicians better understand ketamine response in human patients.

This new study is evaluating how effective psychedelics can be in the treatment of binge eating disorder.

Numinus' Chief Clinical Officer shares resources about the potential use of ketamine in psychiatry.

The first patient has been dosed in the phase 2b dose-optimization trial of a pharmaceutically optimized form of LSD for the treatment of generalized anxiety disorder.

This is the extra table for "Interest Grows in Treatment of Mood Disorders by Classic Psychedelics."

One researcher shares his evidence for the usage of psilocybin in psychiatry.

We have an urgent need for new and improved treatment options for depression—are psychedelic medications the answer?

Treatments alter the neural processes underlying SAD symptoms.

How can psychedelic research incorporate disability inclusion into future work?

What are your thoughts on psychedelics?

Drug comparison has significant implications for dose- and substance-dependence.

Welcome to the psychedelic renaissance.

Psychedelics: returning hope to veterans with PTSD.

What does the movie Dune say about our society’s current relationship with psychedelics?

A kappa-opioid receptor with psychedelic effects, this potential agent for treatment-resistant depression and other disorders will be paired with a digital therapeutic for maximum efficacy.

New research is being conducted on how psychedelic substances may change the future of mental health care. Dr Carlin explained more in her speech at the Annual Psychiatric Times® World CME Conference™.

An exploration of findings from contemporary research that hint at the unexplored hallucinogenic potential of ketamine and considerations for future investigation.

Here: a review of the scientific evidence relevant to the use of classic hallucinogens in the treatment of substance use disorders.